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ABSTRACT
Chronic myeloid leukemia (CML) is a myeloproliferative disease that generates from
malignant transformation of pluripotent hematopoietic stem cells. First line treatment for
CML is the tyrosine kinase inhibitor (TKI), imatinib. For patients resistant or intolerant to
imatinib, other TKIs, dasatinib, nilotinib, and ponatinib, are approved treatments. Patients
who are resistant or intolerant to other agents are started on ponatinib as a last line
option. Common adverse events of ponatinib are hypertension, dry skin, rash, abdominal
pain, constipation, and nausea. More serious adverse effects include cardiovascular
effects, fluid retention, pancreatitis, severe myelosuppression, and hepatotoxicity.
Treatment for these adverse effects can include interrupting ponatinib therapy and
providing symptomatic and supportive care. Reintroduction of agent can be considered
when the serious event has resolved or the potential benefit of resuming therapy is
judged to outweigh the risk. The patient is a 65 year old Caucasian male with a history of
imatinib-resistant CML. The patient was started on ponatinib 45mg approximately 3
months prior to presentation after failure of previous regimens. He requires platelet
transfusions for ponatinib associated thrombocytopenia. He presents with 4 days of new
right flank pain with radiation to his right groin. Evidence of pancreatitis was found on
endoscopic retrograde cholangiopancreatography (ERCP). LFTs were elevated on
admission. The patient had no history of alcohol or steroid use. Ponatinib was
discontinued on admission and within three days the patient’s symptoms of
thrombocytopenia, pancreatitis and hepatotoxicity began to resolve. After complete
resolution of the pancreatitis, the patient was restarted on ponatanib 15mg as an
outpatient. Patients started on ponatinib should have their serum lipase, amylase, liver
enzymes, and platelets checked every 2 weeks for the first 2 months and then monthly.
By checking levels regularly it may allow the physicians to decrease the dose before
complications arise that may require hospitalization. Signs and symptoms of pancreatitis
should also be monitored and started on a low dose to avoid complications.

CASE REPORT

SEVERITY

In the ED (6/3/13), medications used for symptom relief included:

• PEG 3350 1 TBSP PO
• Ondansetron 4 mg IV x 3 doses
• Ammonium Lactate 12% lotion to skin • Pantoprazole 40 mg PO x 2 doses
• Docusate 100mg PO
• Tramadol 50 mg PO x 4 doses
• Fluticasone 50 mcg in each nostril
Due to low platelet count in ED (6,000 platelets/µL) and elevated transaminases,
ponatinib was held. A computed tomography (CT) scan showed an increase in
intra and extrahepatic ducts, common duct, and pancreatic ducts extending to the
ampulla. After an ERCP, evidence of acute pancreatitis was found. Ponatinib was
discontinued on admission (6/4/13), and pancreatitis resolved. Platelet
transfusions were given until platelet count increased. Ponatinib was restarted at
a lower dose of 30 mg following hospital discharge.
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TP (the patient), a 65 year old Caucasian male, presented to the emergency
department (ED) on 6/3 with 4 days of right flank pain with radiation to his right
groin. His pain was variable in severity with no associated nausea, vomiting,
constipation, or diarrhea. In the ED, TP was also found to have thrombocytopenia
and anemia, with platelet count of 6,000/µL, Hgb 12.3g/dL, and Hct 35.9%. TP
displayed no symptoms of overt bleeding. Elevated transaminases were also found
on admission; AST was 284 IU/L, ALT was 185 IU/L with no evidence of jaundice or
liver failure.
Past medical history: Imatinib-resistant CML, platelet transfusion dependent
thrombocytopenia, bilateral non-obstructing nephrolithiasis, GERD, chronic anemia,
hypertension, tubular adenoma, marijuana and tobacco use (52 pack year history;
quit 1/2013; currently uses electronic cigarettes)
Medications prior to admission:
• Tramadol 50 mg PO TID for pain
• Ammonium Lactate 12% lotion to skin
• Ponatinib 45 mg PO daily for CML
BID for dry skin
• Ondansetron 8 mg PO BID prn N
• Amlodipine 5 mg PO daily for HTN
• Docusate NA 100 mg PO BID
• Sinus Rinse 1 packet nasally BID prn
• Dronabinol 5 mg PO BID ac
• PEG 3350 1 TBSP daily mixed in 8 oz
• Hydrocodone/APAP 5/500 mg PO Q6H of water, juice, soda or coffee
prn pain
• Fluticasone 50 mcg spray once in each
nostril daily

OUTCOMES
After ponatinib discontinuation, and the administration of fluid replacement and blood
transfusions, transaminases, platelets and symptoms of pancreatitis normalized.
Following hospital admission, the patient was restarted on a decreased dose of 15
mg daily which was increased after a week to 30 mg. After re-initiation, there were
no signs of pancreatitis or elevated transaminases. Due to low platelet count (33,000
platelets/µL), ponatinib therapy was again discontinued the following month. When
platelet count increased again, the patient was restarted on 15 mg daily. Ponatinib
was eventually discontinued due to lack of efficacy and bosutinib was initiatied.

DISCUSSION
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HISTORY OF PRESENT ILLNESS

The adverse effects were severe. The patient was admitted due to pain,
thrombocytopenia and elevated transaminases. He required daily monitoring for
bleeding, fever and pain. He required daily platelet transfusions and hydration until
ERCP could be performed. Due to the need for an ERCP procedure, the patient
spent additional time in the hospital.
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Graphs depict changes in AST, ALT, and platelet levels over time. Ponatinib was initiated
on 2/13, discontinued 6/4 after presenting to the ED, and resumed at a lower dose on
6/8. Due to the drop in platelet count (6/9) and rise in LFTs, ponatinib was discontinued
again and restarted on 6/14/13. Platelet transfusions (
) were administered until
platelets were ≥ 25,000 for ERCP.

ANALYSIS OF THE REACTION
Use of the Naranjo adverse drug reaction probability scale1,2 indicated a probable
relationship with thrombocytopenia (score of 8) and elevated transaminases (score
of 7). The scale assigned a possible relationship with pancreatitis (score of 4) and
ponatinib in this patient. While the Naranjo scale1 only found a possible-probable
relationship with the adverse events, they were likely to be drug induced. Other
causes of the adverse effects were considered and excluded. Patient was not
taking any other medications that could cause pancreatitis, thrombocytopenia
and/or elevated transaminases and he had no history of alcohol or steroid use.
ERCP ruled out cancer and granuloma. Pancreatitis resolved upon discontinuation
of ponatinib, so galls stones as a cause was ruled out.

For patients who are resistant or intolerant to imatinib, dasatinib, or nasatinib,
physicians could initiate ponatinib. Patients started on CML treatment are routinely
monitored for thrombocytopenia and myelosuppression. Myelosuppresion typically
occurs within the first 4 weeks of therapy and is more common in patients with
advanced disease.3 In the 43 patients with chronic phase CML, treatment-related
thrombocytopenia of grade 3 or more occurred in 12 patients (28%).2
Ponatinib can also cause acute pancreatitis and liver dysfunction. Dose-limiting toxic
effects included pancreatic events, with pancreatitis observed in 14% of patients.
Patients should be educated and monitored on signs and symptoms of pancreatitis.
Cortes et. al discussed that thrombocytopenia and pancreatic are self-limiting once
the drug is discontinued.2 Discontinuation of ponatinib should resolve pancreatitis
symptoms within 2 weeks.2 There is no research evaluating restarting the medication.
However, it is recommended to decrease the dose and serum lipase levels should be
checked every 2 weeks for the first 2 months of initiation, and then monthly
thereafter.3 For patients with history of alcohol abuse, additional serum monitoring
should be considered.4 This case showed that discontinuation of ponatinb allowed the
patient’s labs to normalize. Due to lack of an available alternative agent, the patient
was restarted on ponatinib until patient eventually failed therapy.
On October 31st, Ariad Pharmaceuticals suspended production of ponatinib due to
case reports of life-threatening blood clots and severe narrowing of blood vessels
linking the drug to fatal heart attacks and strokes within two weeks of initiation.5
Ponatinib can only be requested for compassionate use in U.S. however, the
Pharmacovigilance Risk Assessment Committee of the European Medicines Agency
have decided to keep ponatinib on the market with a stronger warning precautions.6
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